BTK and B-cell non-Hodgkin lymphoma: In the Phase I/II TakeAim Lymphoma trial (NCT03328078), emavusertib is showing efficacy in several B-cell NHLs as a single agent and also in combination with the BTK inhibitor ibrutinib, even in patients with prior BTK inhibitor exposure.